A Phase 1b clinical trial involving eight people with multiple sclerosis and four people with neuromyelitis optica, both autoimmune disorders, finds that introduction of dendritic cells engineered to carry specific antigens resulted in production of IL-10, an immune system component that can indicate development of immune tolerance, suggesting that the engineered dendritic cells may induce tolerance to autoimmune targets, according to a study.
###
Article #18-20039: "Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial," by Irati Zubizarreta et al.
MEDIA CONTACT: Lawrence Steinman, Stanford University School of Medicine, CA; tel: 650-725-6401, 415-601-3778; e-mail: < steinman@stanford.edu >; Pablo Villoslada, Stanford University School of Medicine, CA; 650-656-5172; e-mail: < pvillos@stanford.edu >
Proceedings of the National Academy of Sciences